Trump Postpones AI Executive Order Signing Cites Concerns Over Potential Hurdles SP 500 Inches Higher as Healthcare and Tech Rally Offset Telecom Weakness Prediction Markets Signal Growing Odds of Fed Rate Hike by Mid2027 SpaceXs Starlink Revenue Stream Could Be Key to Valuation Amid Potential Nasdaq Listing Energy Efficiency Strategies Offer Potential Winter Savings Experts Suggest Japan Carmakers Face Margin Pressure as Aluminum Prices Surge Supply Risks Loom CKX Lands Inc Q1 2025 Earnings Modest Profit Amid Quiet Quarter STM Q1 2026 Earnings Earnings Miss Weighs on Results but Modest Stock Gain Suggests Broader Resilience REX Q3 2001 Earnings EPS Surges 23 Above Estimates Amidst Volatile Ethanol Market FORTY Q1 2025 Earnings EPS of 123 Reported Amid Stock Decline ZYME Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Reports Wider Loss EM Q2 2024 Earnings Staggering EPS Beat Drives Attention Stock Holds Steady Indigo Acquisition Corp Unit INACU Holds Steady as SPAC Units Trade in Tight Range Haoxin Holdings HXHX Declines 207 Testing Support as Price Hovers Near 049 Putnam Municipal Opportunities Trust PMO Edges Higher Amid Stable Income Demand KORE Group Holdings Holds Steady Near Support as Momentum Builds WilliamsSonoma WSM Holds Steady Near Resistance Key Levels to Watch Oil Prices Surge Past 100 a Barrel as Market Faces Potential Point of No Return Origin Bancorp Inc OBK Q1 2026 Earnings EPS Misses Estimates Despite Solid Operational Performance Gabelli Utility Trust GUT Faces Modest Decline Consolidates Between Key Support and Resistance CPS Technologies Corp CPSH Q1 2026 Earnings EPS Misses Estimates as Stock Gains on Positive Momentum Guardant Health Q1 2026 Earnings NarrowerThanExpected Loss Lifts Shares OFS Q1 2026 Earnings Massive EPS Beat Driven by Strong Portfolio Performance LNZA Q4 2025 Earnings EPS Surprise Beats Estimate by Wide Margin Yet Stock Falls YDKG Q4 2012 Earnings EPS Misses Estimates Amid Challenging Quarter Milestone Pharmaceuticals MIST Q1 2026 Earnings Significant EPS Miss as PreRevenue Biotech Continues Pipeline Development EXFY Q1 2026 Earnings EPS Beats Estimates by 68 as Cost Discipline Drives Profitability